1. J. A. Waschek, G. M. Rubin, T. N. Tozer, R. M. Fielding, W. R. Couet, D. J. Effeney, and S. M. Pond. Dose-dependent bioavailability and metabolism of salicylamide in dogs.J. Pharmacol. Exp. Ther. 230:89–93 (1984).
2. J. A. Waschek, R. M. Fielding, S. M. Pond, G. M. Rubin, D. J. Effeney, and T. N. Tozer. Dose-dependent sulfoconjugation of salicylamide in dogs: effect of sulfate depletion or administration.J. Pharmacol. Exp. Ther. 334:431–434 (1985).
3. R. M. Fielding, J. A. Waschek, D. J. Effeney, A. C. Pogany, S. M. Pond, and T. N. Tozer. Extrahepatic sulfoconjugation of salicylamide in dogs.J. Pharmacol. Exp. Ther. 236:97–102 (1986).
4. J. A. Waschek, R. M. Fielding, T. N. Tozer, D. J. Effeney, and S. M. Pond. Availability of plasma sulfate for conjugation of salicylamide in dogs.Biochem. Pharmacol. 35:544–546 (1986).
5. S. M. Pono, J. A. Waschek, V. Mahachi, R. M. Fielding, D. J. Effeney, and T. N. Tozer. Nonlinear intestinal first-pass metabolism of salicylamide in dogs after portacaval transposition.J. Pharmacol. Exp. Ther. 245 (in press, 1988).